News - Par Pharmaceutical, Generics

Filter

Popular Filters

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

TPG to acquire Par Pharma for $1.9 billion

17-07-2012

Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling

09-04-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent

29-03-2012

Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

Promotions at Par Pharma as firm grows with acquisitions

22-11-2011

US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president…

GenericsManagementPar Pharmaceutical

Back to top